David Hughes Scales
Direktor/Vorstandsmitglied bei CN Bio Innovations Ltd.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Maureen Coleman | F | - |
CN Bio Innovations Ltd.
 CN Bio Innovations Ltd. BiotechnologyHealth Technology CN Bio Innovations Ltd. develops and supplies bioengineered solutions. Its products include liver chip system, tissue flex system, contract research services, drug safety profiling, drug metabolism, bespoke tissue models & applications development and technical support. The company was founded by Dr. Tim Hart on February 28, 2008 and is headquartered in Begbroke, the United Kingdom. | - |
| Paul Brooks | M | - |
CN Bio Innovations Ltd.
CN Bio Innovations Ltd. BiotechnologyHealth Technology CN Bio Innovations Ltd. develops and supplies bioengineered solutions. Its products include liver chip system, tissue flex system, contract research services, drug safety profiling, drug metabolism, bespoke tissue models & applications development and technical support. The company was founded by Dr. Tim Hart on February 28, 2008 and is headquartered in Begbroke, the United Kingdom. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Landon Clay | M | 98 |
GlycoForm Ltd.
 GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Elizabeth Phelps | F | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Mario Polywka | M | 61 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 7 Jahre |
| Gavin David Clark | M | 65 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 3 Jahre |
| Louis Joseph Nisbet | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Benjamin Guy Davis | M | 54 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 9 Jahre |
| Chris Urch | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 7 Jahre |
| Antony J. Fairbanks | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 9 Jahre |
| James Mallinson | M | 63 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Phillip Dolamore | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 12 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Hughes Scales
- Persönliches Netzwerk
